Purpose: Evidence of the effect of vasectomy on prostate cancer is conflicting with the issue of detection bias a key criticism. We examined the effect of vasectomy reversal on prostate cancer risk in a cohort of vasectomized men. Evidence of a protective effect would be consistent with a harmful effect of vasectomy on prostate cancer risk while nullifying the issue of detection bias. Materials and Methods: Data were sourced from a total of 5 population level linked health databases in Australia, Canada and the United Kingdom. Cox proportional hazards regression analysis was used to compare the risk of prostate cancer in 9,754 men with vasectomy reversal to the risk in 684,660 with vasectomy but no reversal. Data from each jurisdiction were combined in a meta-analysis. Results: The combined analysis showed no protective effect of vasectomy reversal on the incidence of prostate cancer compared to that in men with vasectomy alone (HR 0.92, 95% CI 0.70e1.21). Conclusions: These results align with those of previous studies showing no evidence of a link between vasectomy and prostate cancer.
THE effect of vasectomy on the risk of prostate cancer has been widely researched since the early 1990s, when 2 studies revealed an elevated risk of prostate cancer in vasectomized men.
1e3 A large number of additional studies followed with conflicting results. 4e8 Conclusions drawn from meta-analyses and systematic reviews have also been inconsistent, with findings indicating no effect of vasectomy on prostate cancer 9e11 or a small effect. 12e14 Studies on this issue have invariably compared observational data on the risk of prostate cancer between individuals who have and have not elected vasectomy with attempts made to control for confounding factors. One key criticism leveled at many studies which have shown an effect is the issue of detection bias. Prostate cancer is unique in that most cases are not clinically significant and may go undetected during the lifetime of an individual. Prostate cancer is also highly prevalent with a study of autopsy results suggesting around a 25% prevalence of invasive prostate cancer in men older than 50 years. 15 Given this, Accepted for publication March 1, 2018 .
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Several potential biological mechanisms have been suggested through which vasectomy may influence prostate cancer risk. 17 They include known alterations in seminal fluid composition and hormone levels in vasectomized men which could favor the development of malignancy, the production of sperm antibodies in vasectomized men, the reduction in local immune factors which develops in vasectomized men and the promotion of growth factors which favor the development and progression of prostate cancer. 17 The evidence that any of these specific mechanisms increases prostate cancer risk is currently limited. 12 If vasectomy increases the risk of prostate cancer by one of the above mechanisms, individuals in whom vasectomy is reversed might find that the risk of prostate cancer is subsequently lower than in men who remain with vasectomy, at least to the extent that the mechanisms and putative carcinogenic effects are remediable. Comparing vasectomized men with those who have undergone vasectomy reversal provides an alternative way to investigate the risk of vasectomy on prostate cancer. This approach helps reduce the risk of detection bias as all individuals would have originally undergone vasectomy and so have a similar likelihood of prostate cancer screening based on health system engagement.
18
In this study we evaluated whether vasectomy reversal would offer protection against prostate cancer risk in vasectomized men. A finding of such a protective effect would be consistent with a harmful effect of vasectomy on the risk of prostate cancer. Due to the relatively small number of vasectomy reversals our analysis was performed using data from 5 population level, linked health record databases located in Western Australia and New South Wales, Australia; the Province of Ontario, Canada; and Wales and Scotland, the United Kingdom. Results were pooled in a meta-analysis.
METHODS
Data for this study were sourced from 5 regional record linkage centers, including the Western Australian Data Linkage Branch and the Centre for Health Record Linkage, New South Wales, Australia; the Institute for Clinical Evaluative Sciences, Province of Ontario, Canada; and the Information Services Division, Scotland and the SAIL (Secured Anonymized Information Linkage) Databank, Wales, the United Kingdom. Each regional center has linked hospital discharges, mortality and cancer registration data from the respective regions on the individual level. Deidentified linked data extractions took place at each center.
Data were extracted on all individuals treated with a vasectomy procedure. All teams worked from a common data set creation protocol, although specific extraction codes depended on the coding system applied in each jurisdiction. To be included in study individuals needed to be 20 years old or older at the time of vasectomy and have no diagnosis of prostate cancer prior to vasectomy. Teams were instructed to use data from all available years and follow individuals for as long as the data sets allowed. There was no minimum followup for study inclusion.
For each individual in the study extracted data included vasectomy reversal, age at vasectomy/vasectomy reversal, date of vasectomy/vasectomy reversal, date of death if deceased, and date of the first diagnosis of prostate cancer if diagnosed with prostate cancer as determined by an entry in cancer registry data sets.
Cox proportional hazards regression was performed to compare vasectomized men who did and did not undergo vasectomy reversal with time to prostate cancer diagnosis as the outcome. Data were censored at the end of the available study period or at the earlier death of the individual. Vasectomy reversal was included as a time dependent exposure in the model.
Analysis was stratified by age at vasectomy/vasectomy reversal and categorized into 5-year groups to control for potential confounding by age. Analysis of each data set was performed locally by researchers in each jurisdiction. At each participating institution local ethics and data linkage applications were prepared to access the data in that region. The supplementary Appendix (http://jurology. com/) shows further detail on the data sets and codes used to identify cases. The counts of vasectomy and vasectomy reversal cases along with the HR and CI of the age adjusted effect of vasectomy reversal on prostate cancer in vasectomized men were then pooled in a random effects meta-analysis.
RESULTS
Data were received from Western Australia and New South Wales, Australia; the Province of Ontario, Canada; and Wales and Scotland, the United Kingdom. A total of 9,754 men had undergone vasectomy reversal and 684,660 had vasectomy. The table shows the breakdown of the study population by region.
The figure shows the age adjusted HR of each region along with the combined HR. In Wales the vasectomy reversal cohort, which comprised only 88 individuals, did not experience prostate cancer so that HRs could not be estimated for this region. Combined analysis revealed no concrete evidence of a protective effect of vasectomy reversal on the incidence of prostate cancer compared to that in men with vasectomy but without reversal (HR 0.92, 95% CI 0.70e1.21). There was no evidence of result heterogeneity (
DISCUSSION
This study demonstrated no obvious protective effect of vasectomy reversal on prostate cancer in vasectomized men. The results align with previous studies which showed little or no evidence of a link between vasectomy and prostate cancer. Our study had several advantages over previous studies. By comparing vasectomized men with men who underwent vasectomy reversal we avoided the issues of detection bias which have been leveled at previous studies. The use of validated health record databases avoided many issues that occur with selfreporting. The inclusion of more than 600,000 vasectomized men from a total of 3 continents made this arguably the largest study of the issue to date.
The limitations of our study include the restricted number of confounders in the prescribed analysis, that is 5-year age bands only. It is possible that differences existed between those with and without vasectomy reversal which may have affected the prostate cancer risk. Potential factors include the extent of screening for prostate cancer, such as the number of urology visits and testing for prostate specific antigen; the engagement level with the health care system, such as the frequency of general practitioner visits; and a range of risk factors for prostate cancer, such as ethnicity, family history and diet. This information is not present in the administrative data used in this study.
We attempted to control for detection bias by comparing only men who had undergone vasectomy, who would likely have similar levels of health engagement and prostate cancer screening. The vasectomies in this study were performed in hospital settings and, thus, they were likely performed by urologists. However, the Ontario data also included vasectomies done in the primary care setting.
Despite the lengthy followup of our study the peak incidence of prostate cancer diagnosis occurs late in life, which was beyond the followup in most individuals in our study. Longer followup would provide greater certainty in our findings.
The validity of our study relies on the assumption that if vasectomy increases the risk of prostate cancer, this increased risk would be remediated to a measurable extent by vasectomy reversal. The proposed biological mechanisms are amenable to this view. 18 However, it is possible that some alternative 
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Age standardized HRs of time to prostate cancer diagnosis in vasectomy and vasectomy reversal cohorts mechanism may increase the risk of prostate cancer following vasectomy regardless of subsequent vasectomy reversal. Men planning to undergo vasectomy reversal may have received additional screening for prostate cancer, leading to potential denial of vasectomy reversal in those with prostate cancer or suspicion of prostate cancer. This would have resulted in a healthier reversal cohort and could have potentially biased our results toward the finding of a protective effect of vasectomy reversal. Not all vasectomies and vasectomy reversals have been captured. Vasectomies performed in primary care settings rather than in hospital were not captured in this study except in Ontario. In Wales and Scotland vasectomies and vasectomy reversals done outside the public health system are not recorded in administrative collections. In Ontario, Scotland and Wales vasectomy reversals are typically not available under the public system to individuals who simply wish to have more children but only for specific medical reasons. Thus, we can expect that some individuals in the Wales and Scotland vasectomy cohorts underwent private vasectomy reversal, which was not captured in our data, potentially biasing our results towards the null. However, such bias is likely to be small, given the rarity of vasectomy reversals compared to vasectomies.
The absence of recording private vasectomy reversals is the likely cause of the particularly low numbers in Wales. The exclusion of Welsh data from our pooled results due to the lack of prostate cancer outcomes in vasectomy reversal cases had the potential to bias our results upward. However, since the Welsh data represented less than 1% of our total vasectomy reversal cases, any such bias would be minimal.
Previously published results suggest that any effect size, if an effect exists, is likely to be small. Indeed, the most recent systematic review and meta-analysis revealed a statistically significant effect size of only 1.05 and the investigators suggested that this was unlikely to be causal. 12 This result falls within the CIs of the current study and such an effect cannot be ruled out. However, the most parsimonious explanation of our results is that there is no increased prostate cancer risk in vasectomized men. This accords with evidence in a number of high quality studies 5, 7, 8 and several meta-analyses. The difficulty of removing all possible confounders and the apparent small effect size, if any, means that the existence of an effect of vasectomy on prostate cancer would be difficult to establish conclusively through observational epidemiology. Further exploration of this issue should focus on alternate research designs and modalities when possible. Studies that further explore potential biological mechanisms of the proposed link would be valuable contributions. There are limitations worth acknowledging, including the inability to account for several confounders and a short followup relative to the peak age of prostate cancer incidence. Conversely this study may overcome the detection bias that has challenged direct examination of the association between vasectomy and prostate cancer, given that men who choose vasectomy vs those who do not show health seeking behaviors and are more likely to undergo prostate cancer screening.
CONCLUSIONS
These data add another important facet to the synthesized literature demonstrating that by the Hill criteria of causality there is no clinically meaningful causal association between vasectomy and prostate cancer. 1 Thus, prostate cancer risk should not factor into decision making for men considering vasectomy. It is time to put this debate to rest.
